Cutaneous Adverse-Event Reporting Patterns of Bruton Tyrosine Kinase Inhibitors: A Multi-Database Pharmacovigilance Analysis
Background: Bruton tyrosine kinase inhibitors (BTKi) are widely used for B-cell malignancies and chronic graft-versus-host disease, but their real-world dermatologic reporting profile remains incompletely defined. Methods: We performed a multi-database pharmacovigilance analysis of BTKi primary suspect reports in FAERS, Canada Vigilance, and JADER. Outcomes included any-cutaneous adverse event, a prespecified 14-category morphology panel, severe cutaneous reaction controls, cutaneous malignancy, latency, and exploratory wound/ulcer and neutrophilic-dermatosis phenotypes. Reporting odds ratios (RORs), Evans criteria, a mutually exclusive haematologic-oncology disease-context comparator, multivariable models, and cross-database replication were used. Results: FAERS contained 75,681 BTKi primary suspect reports among 12,838,382 reports; Canada Vigilance contained 4649 among 1,234,555; and JADER contained 1822 BTKi suspect reports among 1,027,194. Vascular-cutaneous events showed the most prominent class-level reporting pattern (FAERS ROR 7.97, 95% CI 7.43–8.56; disease-context ROR 6.38, 95% CI 5.84–6.97), with similar disproportionate reporting observed in Canada Vigilance and JADER. Of 802 vascular-cutaneous reports, 777 (96.9%) described bleeding manifestations without vasculitis, whereas 22 (2.7%) included vasculitis as a reported event; cutaneous vasculitis itself was not disproportionately reported (19 reports; ROR 1.38, 95% CI 0.89–2.16). Wound/ulcer events met the Evans criteria for disproportionate reporting in FAERS and were directionally elevated against the full Canada Vigilance background, but not against the Canadian disease-context comparator. Exploratory analyses showed disproportionate reporting for the neutrophilic-core phenotype (disease-context ROR 1.99, 95% CI 1.50–2.66) and pyoderma gangrenosum (ROR 2.87, 95% CI 1.98–4.16). Non-melanoma skin cancer remained disproportionately reported after disease-context adjustment in FAERS (adjusted OR 1.54, 95% CI 1.39–1.71), and was reproduced in Canada Vigilance. A shorter latency period was identified for bleeding than for cutaneous malignancy (median, 1.1 vs. 9.3 months). In SJS/TEN culprit-drug co-exposure analyses, concomitant BTK inhibitor exposure did not show greater disproportionate SJS/TEN reporting than the corresponding culprit-drug-only groups. Conclusions: BTKi-associated dermatologic reports identified three main patterns: early cutaneous bleeding, wound-and-ulcer events with an exploratory neutrophilic-dermatosis component, and later cutaneous malignancy. These findings support the early assessment of bleeding and non-healing ulcers and longer-term skin surveillance during BTKi treatment. Spontaneous-reporting data cannot determine incidence, confirm causality, establish comparative product safety, or accurately adjudicate clinical diagnoses and event timing.
Authors
- Arkadeep Dhali (ORCID: https://orcid.org/0000-0002-1794-2569)
- Saikat Mandal (ORCID: https://orcid.org/0000-0003-1250-5295)
- Manideepa Maji (ORCID: https://orcid.org/0000-0003-2839-5158)
- Ashish Sharma (ORCID: https://orcid.org/0009-0005-2698-0128)
Institutions
- Queen's University Belfast (GB)
- Yale New Haven Hospital (US)
- Nottingham University Hospitals NHS Trust (GB)
- University of Nottingham (GB)
- University of Hull (GB)
- Yale Cancer Center (US)
- Sheffield Teaching Hospitals NHS Foundation Trust (GB)
- Nottingham Biomedical Research Centre (GB)
- Smilow Cancer Hospital (US)
- Imperial College London (GB)
- Hull York Medical School (GB)
Publication Details
- Journal
- Cancers
- Published
- 2026-11-16
- DOI
- https://doi.org/10.3390/cancers18223660
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- UK Research and Innovation
- NIHR Nottingham Biomedical Research Centre